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BACKGROUND

METHODS

The incidence of esophageal adenocarcinoma (EA) has
increased more rapidly than any other cancer (with the
exception of malignant melanoma) in the United States
over the past 30 years. Gastroesophageal reflux disease
(GERD) is the strongest risk factor for the development of
Barrett’s esophagus, which in turn leads to the rise of
most EA’s. In a large portion of persons with sleep
disorders, perhaps as high as 30%, GERD is a major
causal or contributing factor. It has been proposed that
the use of hypnotics for the treatment of sleep disorders
may exacerbate the damaging effects of refluxate on the
esophageal epithelium by reducing the frequency and
effectiveness of normal clearance mechanisms (figure 1).

We performed a retrospective chart review using ICD-9
codes for Barrett’s esophagus and EA to identify patients
with confirmed histologic diagnoses of these conditions.
Patients that met study criteria were queried by telephone
to obtain a history of hypnotic medication use over the 10
years prior to the diagnosis of Barrett’s esophagus or EA.
Hypnotic medications included both benzodiazepines and
non-benzodiazepines (such as zolpidem, zaleplon, and
trazodone). In addition, we obtained an accurate history
regarding their acid reflux symptoms and treatment.

Figure 1: Pathophysiology of hypnotic
medications effect on disordered sleep.

PURPOSE
Our study was developed to track prior use of hypnotic
sleep aids in patients diagnosed with Barrett’s esophagus
and/or esophageal adenocarcinoma.

Table 1: Characteristics of Study Participants on
Sleep Aids at the time of diagnosis with BE or EA.
Diagnosis

Symptoms

Acid suppression

Sleeping Aids

61F

BE, no dysplasia

Acid reflux

PPI (Nexium)

Zolpidem and Duloxetine

52F

BE, no dysplasia

Acid reflux

PPI (Nexium)

Zolpidem

74M

BE, no dysplasia

Acid reflux

PPI (Prilosec)

Zolpidem

62M

BE, no dysplasia

Nocturnal acid reflux

None

Alprazolam

69M

BE, no dysplasia

Indigestion

Calcium carbonate (Tums) PRN

Clonazepam

37M

BE, no dysplasia

Acid Reflux

None

Doxylamine (Unisom)

55M

EA arising from BE

Acid Reflux

PPI (Protonix)

Zolpidem

70M

BE, no dysplasia

Acid Reflux

PPI (Nexium)

Zolpidem

44F

BE, no dysplasia

Acid Reflux

Famotidine PRN

Zolpidem and Quetiapine

66M

BE, no dysplasia

None

PPI (Nexium)

Clonazepam and Quetiapine

60M

BE, no dysplasia

Acid Reflux

PPI (Nexium)

Diphenhydramine and Fluoxetine

51F

BE, no dysplasia

Acid Reflux

None

Trazodone, Buproprion and
Escitalopram

70M

BE, no dysplasia

Dysphagia

None

Temazepam

85M

BE, no dysplasia

None

None

Diphenhydramine

CONCLUSION
These studies indicated several important findings:
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1. Sleep aid usage is lower then expected in the general
population (some publications estimate that upwards
of 25% of Americans use sleeping aids) suggesting
that in this study patients with Barrett’s have less
disordered sleep as compared to historical population.
2. Some patients with disordered sleep and Barrett’s are
on sleep aids but not acid suppression medication
suggesting that disordered sleep and GERD with
Barrett’s should be carefully evaluated for PPI
management in conjunction with sleep aid usage.

